LveGun, Re: the 64% safety reference, I think the
Post# of 148288
(Total Views: 448)
Posted On: 08/11/2020 3:38:14 PM
LveGun,
Re: the 64% safety reference, I think the PR said it more colloquially (1st paragraph on Safety)....
"Safety Endpoints:
The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
I agree with the other line of thinking being expressed today, that this data is just going to have to be explained to the larger audience of investors via MSMedia. Individual investors are less likely to "get it" without Lou Dobbs, etc., esssplainin' it to them. With "news alerts", some real reporting, and of course up listing, I am confident we'll see sparks flying. Let's get some jabbering going in the MSM!!
Re: the 64% safety reference, I think the PR said it more colloquially (1st paragraph on Safety)....
"Safety Endpoints:
The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
I agree with the other line of thinking being expressed today, that this data is just going to have to be explained to the larger audience of investors via MSMedia. Individual investors are less likely to "get it" without Lou Dobbs, etc., esssplainin' it to them. With "news alerts", some real reporting, and of course up listing, I am confident we'll see sparks flying. Let's get some jabbering going in the MSM!!
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼